Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial

Martin Schuler, J. C H Yang, K. Park, J. H. Kim, Jaafar Bennouna, Y. M. Chen, C. Chouaid, Filippo De Marinis, J. F. Feng, Francesco Grossi, D. W. Kim, X. Liu, S. Lu, J. Strausz, Y. Vinnyk, R. Wiewrodt, C. Zhou, B. Wang, Vikram K. Chand, D. PlanchardClaudia Bagnes, Claudio Marcelo Martin, Gonzalo Recondo, Juan Jose Zarba, Cesar R. Blajman, Martín Richardet, Sue Anne McLachlan, Phillip Parente, Craig Underhill, Catherine Crombie, P. Mainwaring, Richard Greil, Y. Humblet, Frederique Bustin, Luciano Carestia, Danny Galdermans, Marc Lambrechts, Laetitia Delval, Piet Vercauter, Caicun Zhou, Jin Wang, Cheng Huang, Xiaoyan Lin, Yilong Wu, Xiaoqing Liu, Ying Cheng, Shukui Qin, Jifeng Feng, Jianjin Huang, Yiping Zhang, Shun Lu, Manuela Zereu, Bernardo Garicochea, Cyntia Albuquerque Zadra, Henrik Riska, Tuomo Alanko, Jacques Cadranel, Christos Chouaid, Gérard Zalcman, Denis Moro Sibilot, Maurice Perol, David Planchard, Jaafar Bennouna, Pierre Fournel, Radj Gervais, Maciej Rotarski, Bruno Coudert, Michael Thomas, Thomas Wehler, Martin Faehling, Ulrich Keilholz, Eckart Laack, J. von Pawel, Rudolf Huber, Nicolas Dickgreber, Rainer Wiewrodt, Z. Mark, S. Tehenes, Janos Strausz, Veronika Sarosi, Kumar Prabhash, Minish Jain, Srinivasan Venkatesan, Lalit Sharma, Hemant Dadhich, Rajnish Vasant Nagarkar, Amir Onn, Maya Gottfried, Solomon Stemmer, M. R. Migliorino, Francesco Grossi, Alessandra Bearz, Alessandra Bearz, Cesare Gridelli, Marco Platania, Marco Platania, Giovanni Ceresoli, Giorgio Cruciani, Francisco Gutierrez Delgado, José Luis Gonzalez Perez, Gabriela Alvarado Luna, Othon Padilla Baca, Joachim Aerts, Jos Stigt, Anne Marie C Dingemans, Gerarda Herder, Steven Gans, Jorge Fernando Salas Sánchez, Renzo Luzgardo Alvarez Barreda, Wilbert Rodriguez Pantigoso, Osbert Luis Mejia Palomino, Piotr Jaskiewicz, Andrzej Kazarnowicz, P. Serwatowski, Aleksandra Szczesna, J. Jassem, Vladimir Lubennikov, Nina Karaseva, S. Orlov, Yuri Ragulin, Pilar Garrido, José Luis González Larriba, Carlos Camps, Rosario García Campelo, Pilar Lianes, Manuel Cobo, Enriqueta Felip, Dong Wan Kim, Sang We Kim, Keunchil Park, Joo Hang Kim, Ji Youn Han, Young Chul Kim, Chih Hsin Yang, Te Chun Hsia, Yuh Min Chen, Ying Huang Tsai, Gee Chen Chang, Thomas Chang Yao Tsao, Wu Chou Su, Ming Shyan Huang, Ching Liang Ho, Ruey Kuen Hsieh, Yuriy Vinnyk, Oleksandr Popovych, Olga Ponomarova, Igor Bondarenko, Iryna Polishchuk, Riyaz Shah, Sanka Mitra, Sanjaykumar Popat, James Spicer, Elizabeth Toy, Toby Talbot, Emma Brown, Sunil Upadhyay, Y. Summers, Jayne Gurtler, Luis Meza, John Thropay

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences